Cite
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
MLA
Papadimitrakopoulou, V. A., et al. “Osimertinib versus Platinum–pemetrexed for Patients with EGFR T790M Advanced NSCLC and Progression on a Prior EGFR-Tyrosine Kinase Inhibitor: AURA3 Overall Survival Analysis.” Annals of Oncology, vol. 31, no. 11, Nov. 2020, pp. 1536–44. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.08.2100.
APA
Papadimitrakopoulou, V. A., Mok, T. S., Han, J.-Y., Ahn, M.-J., Delmonte, A., Ramalingam, S. S., Kim, S. W., Shepherd, F. A., Laskin, J., He, Y., Akamatsu, H., Theelen, W. S. M. E., Su, W.-C., John, T., Sebastian, M., Mann, H., Miranda, M., Laus, G., Rukazenkov, Y., & Wu, Y.-L. (2020). Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Annals of Oncology, 31(11), 1536–1544. https://doi.org/10.1016/j.annonc.2020.08.2100
Chicago
Papadimitrakopoulou, V.A., T.S. Mok, J.-Y. Han, M.-J. Ahn, A. Delmonte, S.S. Ramalingam, S.W. Kim, et al. 2020. “Osimertinib versus Platinum–pemetrexed for Patients with EGFR T790M Advanced NSCLC and Progression on a Prior EGFR-Tyrosine Kinase Inhibitor: AURA3 Overall Survival Analysis.” Annals of Oncology 31 (11): 1536–44. doi:10.1016/j.annonc.2020.08.2100.